Evidence map›Paper›PMID 40104940›Full record

ArticleVirulence2025

Multifaceted quorum-sensing inhibiting activity of 3-(Benzo[d][1,3]dioxol-4-yl)oxazolidin-2-one mitigates

Yi Wu, Fulong Wen, Shiyi Gou, Qiman Ran, Yiwen Chu, Wenbo Ma, Kelei Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Study on the antibacterial effect of the new anti-biofilm inhibitor ICAC onFrontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi WuAntibiotics Research and Re-Evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, Sichuan, China.ORCID 0000-0003-1187-921X
Fulong WenAntibiotics Research and Re-Evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, Sichuan, China.
Shiyi GouAntibiotics Research and Re-Evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, Sichuan, China.
Qiman RanAntibiotics Research and Re-Evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, Sichuan, China.
Yiwen ChuAntibiotics Research and Re-Evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, Sichuan, China.
Wenbo MaAntibiotics Research and Re-Evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, Sichuan, China.
Kelei ZhaoAntibiotics Research and Re-Evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, Sichuan, China.ORCID 0000-0002-2515-065X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As antibiotic resistance escalates into a global health crisis, novel therapeutic approaches against infectious diseases are in urgent need.

Indexed as

Anti-Bacterial AgentsPseudomonas aeruginosaQuorum SensingAnimalsBiofilmsCaenorhabditis elegansGene Expression Regulation, BacterialGlycolipidsMolecular Docking SimulationPseudomonas InfectionsVirulenceVirulence FactorsAnti-Bacterial AgentsGlycolipidsVirulence FactorsAnti-virulence drugsinhibitoroxazolidinonePseudomonas aeruginosaquorum-sensingvirtual screening

Identifiers

PMID40104940
PMCPMC12915424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.